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Transcatheter Closure of Atrial
Septal Defect: Are We
There Yet?*
P. SYAMASUNDAR RAO, MD, FACC
Saint Louis, Missouri
Surgical closure of ostium secundum atrial septal defects
(ASDs) can be performed successfully with low (,1%) mor-
tality. However, the morbidity associated with general anesthe-
sia, thoracotomy, cardiopulmonary bypass, postoperative mon-
itoring in the intensive care unit and several days of hospital
stay is considerable. The expense associated with this morbid-
ity, operative scar and psychologic trauma to the patient and
parents are additional disadvantages of surgical treatment. For
these reasons, several groups of cardiologists, for the past two
and one-half decades, have been investigating transcatheter
methods to close the ASDs. The pioneering works of King and
colleagues (1–3) and Rashkind and colleagues (4–6) have
paved the way in these efforts. King designed paired, opposed,
Dacron-covered, stainless steel umbrellas collapsed into a
capsule attached to the tip of the catheter that were implanted
across the atrial septum through a 23F sheath. Because of the
large delivery sheath, requiring cutdown, and complexity of the
procedure, King neither continued the investigation nor did
other cardiologists adopt this method. Rashkind designed a
single, foam-covered umbrella with miniature hooks with an
elaborate centering mechanism and applied it to animal mod-
els and human subjects (4–6). The device and delivery system,
although less bulky than King’s device, still required a 16F
sheath for device implantation. Because of the difficulties
associated with implantation of the hooked device, Rashkind
introduced a double-disk system, similar to his patent ductus
arteriosus occluding device (6). This double-disk device was
later modified by Lock et al. (7); this device is without hooks
but with a bend in the arms of the device and uses spring
tension to allow arms of the device to fold against each other
and has been named the Clamshell device. This device requires
an 11F sheath for implantation. Although the initial clinical
trials with the device were encouraging, development of frac-
tures of the arms of the device and embolization (8,9) forced
the investigators and the Food and Drug Administration to
withdraw the device (in 1991) from further clinical trials. A
buttoned double-disk device that can be implanted through an
8F sheath was developed by Sideris et al. (10). Single institu-
tional (11–15) and multi-institutional (16–18) clinical trials
began. At the time of last review (19), nearly 800 devices had
been implanted and, at present .1,000 ASDs have been closed
with the buttoned device (Sideris EB, personal communica-
tion, November 1997).
Over the past few years, a large variety of other devices
have suddenly emerged. These include the monodisk device of
Pavc˘nick et al. (20), Das-Angel Wing self-centering device
(21), the atrial septal defect occluding system (ASDOS)
(22,23), the Amplatz septal occluder (24) and the redesigned
Clamshell (the CardioSeal device) (25). Clinical trials within or
outside the United States have just begun with the majority of
these devices.
In this issue of the Journal, Thanopoulos et al. (26) present
preliminary results of their experience with the Amplatzer
septal occluder. The device consists of two self-expandable
round disks connected to each other with a 4-mm wide waist
(Fig. 1 in Thanopoulos et al. [26]), made of 0.004- to 0.005-in.
Nitinol wire mesh and filled with Dacron fabric (24,26).
Eighteen of the 22 patients evaluated met echocardiographic
criteria for device closure, and of these 18 patients with intent
to close, 16 (89%) underwent successful device implantation;
in the remaining 2, closure was not attempted because of the
large, stretched diameter of the ASD. Misplacement of the
device occurred in one patient (6%), but the disks of the device
were withdrawn into the delivery sheath and device redeployed
successfully. Complete occlusion of the defect by angiography
and color Doppler echocardiography was demonstrated in 13
patients (81%). The follow-up duration was short, 1 to 3
months. Residual shunt was present in only one patient (6%)
at 3-month follow-up. As I began writing this editorial in late
November 1997, I was under the impression that the report by
Thonopoulos et al. (26) was the first clinical report, but before
I completed this editorial, my attention was drawn to the
report by Masura et al. (27) in the December 1997 issue of
Catheterization and Cardiovascular Diagnosis. They also report
their preliminary experience with the Amplatzer. Their results
in 30 patients are similar to those reported by Thanopoulos et
al. (26).
The advantages of the Amplatzer device appear to be small
delivery sheath, ease with which the method of implantation is
learned and the ability to retrieve and reposition the device
(without damaging it) before release. However, the high
success rate may, in part, be related to relatively small-sized
defects that were occluded. It remains to be seen whether such
results are maintained when more variable-sized defects are
closed and when the method is applied to larger groups of
patients than are presented the report by Thanopoulos et al.
(26).
The authors state that the waist of the device, stenting the
defect, is the major support for device retention, but I suspect
that the disks on either side of the septum also play a role in
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the device stability, and the investigators may have to pay
greater attention to the size of the disks as well.
The bulkiness of the device, as seen on the cineradiographic
and echocardiographic frames, is of some concern, although no
adverse effects related to this were observed. The device’s
metallic frame is completely exposed within the heart, which
may increase thrombogenicity and is of concern, but neither
Thoropoulos et al. nor Masura et al. observed such problems.
Finally, one has to wait for follow-up studies to see whether
“stress” fractures develop with time.
The procedures of echocardiographic selection, catheter-
ization and cineangiography to exclude other anomalies (par-
ticularly anomalous pulmonary venous return) and balloon
sizing of the ASD (28–30) appear to be very similar with all
transcatheter-deployed devices. The sizing of the delivery
sheath used for device deployment varies with the device
(Table 1); the Amplatzer appears to require a smaller delivery
sheath than the other devices. Retrieval of the device before
release is possible with most devices but appears to be much
simpler with the Amplatzer and without damaging the device.
Transcatheter device retrieval after its release, should it be
required, was not addressed by Thonopoulos et al. (26) or by
Masura et al. (27), and I suspect that it may be difficult.
Similarly, surgical retrieval may be problematic. The authors
state that their device, along with the Das-Angel Wing and
Pavc˘nik Monodisk, are the only devices with a self-centering
mechanism. To this should be added the centering buttoned
device (31), which also has self-centering characteristics but
requires an 11F sheath for device delivery.
When one compares the preliminary results of this device
with similar preliminary experiences with other devices (Table
2), the results, in terms of percent implantation feasibility in
patients with intent to close, success of implantation, device
dislodgment frequency and effective occlusion rates are com-
parable. Late follow-up results are not available for the
Amplatzer, and when they are available, they should be
scrutinized and compared with those of other new devices as
well as with those of the buttoned device, which has the largest
clinical experience to date (19; Sideris EB, personal commu-
nication, November 1997). The majority of devices are either
not in use or are under clinical investigation within or outside
the United States (Table 1).
All these devices are only useful for closing small- to
medium-sized ASDs with adequate septal rims and do not
address ASDs that have small and inadequate rims and ostium
primum defects. For this reason, a significant proportion of
these defects cannot be closed with the devices that are
currently under clinical trial and therefore require operation.
Preliminary data from Sideris et al. (33) suggest that such
defects with inadequate rims can be occluded by a balloon-
based buttoned device. The device consists of a detachable
latex balloon occluder attached to a button loop and a loading
wire in a manner similar to the buttoned device (17) and a
counteroccluder. The deflated balloon, after delivery into the
left atrium, is filled with sufficient diluted contrast material to
make it slightly larger than the stretched diameter of the ASD
and is wedged against the defect. A counteroccluder is then
delivered into the right atrium and buttoned across the defect.
The balloon gradually deflates over the next 60 days, by which
time the flattened balloon is endothelized, thus closing the
defect. Preliminary results of the method in animal models and
in human subjects (33) is encouraging. Similar innovative
designs to close large defects with small margins should be
developed in the future.
In summary, a large variety of devices have been developed
to occlude ASDs. Most of the devices have either been
withdrawn or are under clinical investigation (Table 1). The
results with the newest of the devices, the Amplatzer, de-
scribed in Thanopoulos et al. (26) are encouraging and are
comparable with preliminary experiences with other devices.
Experience with larger groups of patients and longer follow-up
Table 1. Atrial Septal Closure Devices
Device
Delivery
Sheath Size Clinical Trial Status
King and Mills interlocking umbrellas 23F Inactive
Rashkind hooked device 16F Inactive
Rashkind double-disk device 11F Inactive
Lock Clamshell device 11F Inactive
Sideris buttoned device 8F/9F Phase II trials
Das Angel Wing device 11F Phase II trials
Sideris centering buttoned device 11F Clinical trials outside
the U.S.
ASDOS 11F Clinical trials outside
the U.S.
Amplatzer 7F/8F Phase I trials
CardioSeal 11F Phase I trials
ASDOS 5 Atrial septal defect occluding system.




Taken to Cath Lab
With Intent to Close
No. (%) of Subjects
in Whom Device
Was Implanted




No. (%) of Subjects
with Effective
Occlusion*
Clamshell (32) 40 34 (85%) 2 (6%) 12 (63%)†
Buttoned (17) 200 180 (90%) 12 (7%) 154 (92%)
Amplatzer (27) 18 16 (89%) 1 (6%) 13 (81%)
*Effective occlusion defined as no or trivial residual shunt. †Nineteen of 32 subjects had adequate imaging studies;
12 (63%) of these had no residual shunt. Cath Lab 5 catheterization laboratory.
1118 RAO JACC Vol. 31, No. 5
EDITORIAL COMMENT April 1998:1117–9
are needed before making any definitive conclusions. Future
research should focus on innovative methods to nonsurgically
close large defects with deficient septal rims.
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